Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
ACS Medicinal Chemistry Letters|October 18, 2019
Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander KillingJuliet A Costoplus, Karen H Veale, Qifeng Qiu, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Synthesis and Evaluation of Camptothecin Antibody-Drug ConjugatesWei Li, Karen H Veale, Qifeng Qiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher, Leonel Ochoa, Lisa A Hammond, et al.
Molecular Cancer Therapeutics|May 25, 2016
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating ActivityMichael L Miller, Nathan E Fishkin, Wei Li, et al.
Cancer Research|March 4, 2010
Antibody-maytansinoid conjugates designed to bypass multidrug resistanceYelena V Kovtun, Charlene A Audette, Michele F Mayo, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Bioconjugate Chemistry|September 11, 2015
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander KillingWayne C Widdison, Jose F Ponte, Jennifer A Coccia, et al.
Molecular Cancer Therapeutics|February 15, 2018
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)Michael L Miller, Manami Shizuka, Alan Wilhelm, et al.
Molecular Cancer Therapeutics|May 20, 2016
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer CellsRajeeva Singh, Yulius Y Setiady, Jose Ponte, et al.
Pageof 3